TriSalus Life Sciences

Q2 FY2026 EarningsQ2 FY26 results beat consensus across the top and bottom lines: revenue of $11.4M exceeded the $10.3M expectation (+11.10%), and Diluted EPS loss of -$0.16 was narrower than the expected -$0.155 mean (when considering the mid-point of -$0.145). Gross margin reached 86.8% vs. 86.1% expected, driven by reduced manufacturing costs. FY26 revenue guidance was maintained at $54M-$57M, in line with market expectations, while the cash position of $46.3M provides runway for continued commercial expansion.